SCHEMBL7718907

SCHEMBL7718907

CCCC(CCC(=O)OCC)P(=O)(O)OCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
CYP1A2 P05177 1/20 0.37
ENPP2 Q13822 6/20 0.36
LPAR1 Q92633 3/20 0.36
LPAR3 Q9UBY5 3/20 0.36
LPAR6 P43657 1/20 0.36
LPAR4 Q99677 1/20 0.36
LPAR5 Q9H1C0 1/20 0.36
LPAR2 Q9HBW0 1/20 0.36
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
ALOX15 P16050 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
ATM Q13315 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7452145 0.85 L3MBTL1 (0.44) L3MBTL1KMT2APOLBCYP1A2ENPP2
SCHEMBL7718880 0.80 L3MBTL1 (0.42) L3MBTL1KMT2APOLBCYP1A2ENPP2
SCHEMBL8996441 0.78 ALDH1A1 (0.38) POLBMGAMGAASIMGAM2
SCHEMBL7718811 0.76 L3MBTL1 (0.45) L3MBTL1KMT2APOLBCYP1A2MGAM
SCHEMBL11328711 0.75 KMT2A (0.43) L3MBTL1KMT2APOLBCYP1A2ENPP2
SCHEMBL7715959 0.75 ALDH1A1 (0.41) CYP1A2MGAMGAASIMGAM2
SCHEMBL25186835 0.73 L3MBTL1 (0.49) L3MBTL1KMT2APOLBCYP1A2MGAM
SCHEMBL6067665 0.73 L3MBTL1 (0.49) L3MBTL1KMT2APOLBCYP1A2MGAM
SCHEMBL27789916 0.73 FDPS (0.47) KMT2AENPP2LPAR1LPAR3LPAR6
SCHEMBL27811505 0.73 FDPS (0.47) KMT2AENPP2LPAR1LPAR3LPAR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed